Imagine tiny particles so small they can sneak past the brain's natural security fence. This project builds a high-tech 'security scanner' and testing kit to see if these particles cause damage. It replaces slow animal tests with fast, computer-aided lab models to keep people safe.
Companies producing nanomaterials face high costs and long delays because there are no standardized OECD or ISO guidelines to test if their products damage the human brain.
A set of high-resolution imaging techniques, high-throughput neurotoxicity assays, and in vitro-in vivo bridging models to predict brain health impacts.
If you are a drug delivery system developer dealing with uncertainty about how nano-carriers affect the brain — this project developed new in vitro models and imaging that reduce the need for animal testing. This helps you prove safety faster to regulators.
If you are a specialty nanomaterial producer dealing with expensive REACH dossier requirements — this project developed read-across schemes and grouping methods. This allows for more cost-effective data collection for regulatory filings.
If you are a nano-implant manufacturer dealing with the risk of long-term neurotoxicity — this project developed high-resolution imaging to track material changes in biological matrices. This ensures your product doesn't cause irreversible CNS damage.
The project supports grouping and read-across schemes for ECHA, which enables more cost-effective data collection for REACH dossiers. It also aims to shorten the time to market for innovators.
Based on available project data, the project focuses on high-throughput and high-content analysis, which are designed for efficient, large-scale screening of materials.
The provided data does not specify the IP or licensing terms; however, it mentions making techniques and methodologies accessible for industry.
It specifically addresses gaps in OECD and ISO guidelines for neuro-nanotoxicity and supports ECHA's requirements for REACH dossiers.
The project runs from 2023-01-01 to 2026-12-31, with imaging methods being developed and validated during the first 36 months.
The consortium is highly commercially oriented, featuring 12 partners from 9 countries with a 50% industry ratio (6 companies). The heavy presence of 6 SMEs suggests the project is designed for practical, scalable application rather than just academic theory, combining expertise from RTOs and universities to bridge the gap between lab research and industrial use.
Contact the International Iberian Nanotechnology Laboratory in Portugal
Contact us to find out how to integrate these neuro-nanotoxicity protocols into your product safety pipeline.
